B. van de Wiel

1.1k citations

21 papers · 144 indexed · h-index 6

Co-authors: Christian U. Blank John B.A.G. Haanen Ton N. Schumacher Adriaan D. Bins Jane Harper Bent K. Jakobsen Hanno L. Tan Annelies Jorritsma
Topics: Cutaneous Melanoma Detection and Management (10 papers)Melanoma and MAPK Pathways (8 papers)CAR-T cell therapy research (6 papers)
Cited by: Oncology Immunology Genetics
Journals: Journal of Clinical Oncology Annals of Oncology European Journal of Cancer
Partner nations: Netherlands Australia Poland

In The Last Decade

B. van de Wiel

17 papers receiving 143 citations

Peers

Countries citing papers authored by B. van de Wiel

Since Specialization

Citations

This map shows the geographic impact of B. van de Wiel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. van de Wiel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. van de Wiel more than expected).

Fields of papers citing papers by B. van de Wiel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. van de Wiel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. van de Wiel. The network helps show where B. van de Wiel may publish in the future.

Co-authorship network of co-authors of B. van de Wiel

This figure shows the co-authorship network connecting the top 25 collaborators of B. van de Wiel. A scholar is included among the top collaborators of B. van de Wiel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. van de Wiel. B. van de Wiel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA57 Two-year clinical update and first biomarker analyses of the phase III NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma 2025 ·Annals of Oncology ·(unknown),(unknown),(unknown),(unknown),Marta López‐Yurda,Richard A. Scolyer,B. van de Wiel,Robyn P.M. Saw,A. Kuijpers,(unknown),Joyce Sanders,(unknown),Jan Willem de Groot,(unknown),(unknown),(unknown),Shahneen Sandhu,Astrid A.M. van der Veldt,(unknown),(unknown)	0
2	1943P Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort 2024 ·Annals of Oncology ·(unknown),Elizabeth M. Burton,Ashley Cimino‐Mathews,Tricia R. Cottrell,Carlos E. de Andrea,(unknown),Jeffrey E. Gershenwald,(unknown),Jane L. Messina,Roberto Salgado,Christian M. Schürch,Raja R. Seethala,Lynette M. Sholl,Sabina Signoretti,M.T. Tetzlaff,B. van de Wiel,Xiaowei Xu,Richard A. Scolyer,Janis M. Taube	0
3	LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial 2024 ·Annals of Oncology ·(unknown),(unknown),Marta López‐Yurda,Richard A. Scolyer,B. van de Wiel,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Jan Willem de Groot,(unknown),(unknown),(unknown),Shahneen Sandhu,Astrid A.M. van der Veldt,(unknown),(unknown)	6
4	1118P Immunological alterations during neoadjuvant BRAF/MEK inhibition in patients with prior unresectable regionally advanced melanoma: Translational analysis from the REDUCTOR trial 2024 ·Annals of Oncology ·(unknown),(unknown),Tom Seijkens,(unknown),B. van de Wiel,(unknown),(unknown),(unknown),Alexander C. J. van Akkooi,J.B.A.G. Haanen	0
5	1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma 2023 ·Annals of Oncology ·Irene L. M. Reijers,Petros Dimitriadis,Alexander M. Menzies,Ellen Kapiteijn,Astrid A.M. van der Veldt,Karijn P.M. Suijkerbuijk,Geke A.P. Hospers,Winan J. van Houdt,Robyn P.M. Saw,Annegien Broeks,Sten Cornelissen,Lindsay G. Grijpink-Ongering,Thomas E. Pennington,Andrew J. Colebatch,B. van de Wiel,Richard A. Scolyer,Alexander C. J. van Akkooi,Georgina V. Long,Christian U. Blank	2
6	1112P Five-year survival after intermittent targeted therapy and anti-PD1 in stage IV melanoma: An update of the IMPemBra trial 2023 ·Annals of Oncology ·Lianne Hoeijmakers,(unknown),Marta López‐Yurda,Lindsay G. Grijpink-Ongering,(unknown),B. van de Wiel,(unknown),Ayşegül Sarı,Stijn W. T. P. J. Heijmink,Daan van den Broek,Annegien Broeks,Jan Willem de Groot,Marieke A. Vollebergh,Sofie Wilgenhof,(unknown),John B.A.G. Haanen,Christian U. Blank	1
7	1096P Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma 2023 ·Annals of Oncology ·(unknown),Elisa A. Rozeman,Judith M. Versluis,Alexander M. Menzies,Hanna Eriksson,B. van de Wiel,Richard A. Scolyer,(unknown),Henk Mallo,Maria Gonzalez,(unknown),(unknown),Lindsay G. Grijpink-Ongering,John B.A.G. Haanen,Alexander C. J. van Akkooi,Georgina V. Long,Christian U. Blank	1
8	797P Relapse-free survival (RFS) update and first translational analyses of DONIMI, a study testing personalized neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage III melanoma patients (pts) based on the interferon-gamma signature (IFN-γ sign) algorithm 2022 ·Annals of Oncology ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Andrew J. Spillane,Richard A. Scolyer,B. van de Wiel,Alexander C. J. van Akkooi,Georgina V. Long,(unknown)	2
9	6P Response and survival according to the interferon-gamma (IFN-γ) signature and tumor mutational burden (tmb) in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma 2022 ·Immuno-Oncology Technology ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Astrid A.M. van der Veldt,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Richard A. Scolyer,B. van de Wiel,(unknown),Alexander C. J. van Akkooi,(unknown),(unknown)	3
10	The value of lymph node ultrasound and whole body 18F-FDG PET/CT in stage IIB/C melanoma patients prior to SLNB 2021 ·European Journal of Surgical Oncology ·(unknown),Bernies van der Hiel,Annemarie Bruining,B. van de Wiel,Yvonne Schrage,Michel W.J.M. Wouters,Winan J. van Houdt,Alexander C. J. van Akkooi	4
11	P01.15 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in macroscopic stage III melanoma patients stratified according to interferon-gamma (IFN-gamma) signature – the DONIMI study 2020 ·(unknown),(unknown),Petros Dimitriadis,Oscar Krijgsman,(unknown),Sten Cornelissen,(unknown),Judith M. Versluis,Disha Rao,B. van de Wiel,Andrew J. Spillane,Richard A. Scolyer,(unknown),Alexander C. J. van Akkooi,(unknown),(unknown)	1
12	Multicenter phase I/IIa study using T cell receptor gene therapy in metastatic melanoma. 2018 ·Journal of Clinical Oncology ·Maartje W. Rohaan,(unknown),Raquel Gomez-Eerland,Maaike van Zon,Renate de Boer,(unknown),Loes M. Pronk,B. van de Wiel,Bastiaan Nuijen,Marnix Geukes Foppen,Johannes V. van Thienen,Christian U. Blank,John B.A.G. Haanen	1
13	Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection, REDUCTOR trial 2018 ·Annals of Oncology ·(unknown),Maartje W. Rohaan,W. Martin C. Klop,Bernies van der Hiel,B. van de Wiel,Daniel S. Peeper,Alexander C. J. van Akkooi,J.B.A.G. Haanen	2
14	External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC): Effect of adding EORTC sentinel node (SN) tumor burden criteria on prognostic accuracy in stage III. 2018 ·Journal of Clinical Oncology ·Max F. Madu,Viola Franke,B. van de Wiel,W. Martin C. Klop,Katarzyna Jóźwiak,Michel W.J.M. Wouters,Alexander Christopher Jonathan Van Akkooi	9
15	Concurrent Merkel Cell Carcinoma and Melanoma in Individual Patients Presents a Treatment Challenge: A Case Series 2017 ·Max F. Madu,(unknown),B. van de Wiel,Margot Tesselaar,Alexander C. J. van Akkooi	0
16	Downsizing of locally advanced stage III (bulky) BRAF V600E/K melanoma with combination targeted therapy to achieve R0 resection 2017 ·European Journal of Cancer ·J.B.A.G. Haanen,(unknown),(unknown),Henk Mallo,S. Adriaansz,Sylvia ter Meulen,Max F. Madu,Loes M. Pronk,Bernies van der Hiel,B. van de Wiel,Daniel S. Peeper,Alexander C. J. van Akkooi	3
17	Risk Factors for Positive Deep Pelvic Nodal Involvement in Patients with Palpable Groin Melanoma Metastases: Can the Extent of Surgery be Safely Minimized? 2015 ·Annals of Surgical Oncology ·(unknown),Alexander C. J. van Akkooi,Harald J. Hoekstra,Han J. Bonenkamp,(unknown),(unknown),Johannes H. W. de Wilt,Bernies van der Hiel,B. van de Wiel,Senada Koljenović,Dirk J. Grünhagen,C. Verhoef	7
18	Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor 2015 ·Molecular Therapy ·Joost H. van den Berg,Raquel Gomez-Eerland,B. van de Wiel,(unknown),Daan van den Broek,Adriaan D. Bins,Hanno L. Tan,Jane Harper,Namir J. Hassan,Bent K. Jakobsen,Annelies Jorritsma,Christian U. Blank,Ton N. Schumacher,John B.A.G. Haanen	88
19	Cu-Sn Transient Liquid Phase Wafer Bonding: Process Parameters Influence on Bonded Interface Quality 2013 ·ECS Transactions ·(unknown),(unknown),(unknown),B. van de Wiel,(unknown),Viorel Drăgoi	6
20	Metastasis from breast cancer to an endometrial polyp; treatment options and follow-up. Report of a case and review of the literature. 2011 ·PubMed ·Angelo B. Hooker,(unknown),B. van de Wiel,Maud M. Geenen	6

About B. van de Wiel

B. van de Wiel is a scholar working on Oncology, Molecular Biology and Immunology, having authored 21 papers that have together received 144 indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (10 papers), Melanoma and MAPK Pathways (8 papers) and CAR-T cell therapy research (6 papers). The work is most often cited by research in Oncology (120 citations), Immunology (70 citations) and Genetics (26 citations). B. van de Wiel has collaborated with scholars based in Netherlands, Australia and Poland. Frequent co-authors include Christian U. Blank, John B.A.G. Haanen, Ton N. Schumacher, Adriaan D. Bins, Jane Harper, Bent K. Jakobsen, Hanno L. Tan, Annelies Jorritsma, Namir J. Hassan and Daan van den Broek. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact